Peptide Compounding Update: New Federal and Utah Guidance Creates a Limited Path Forward

HHS and Utah DOPL announce coordinated enforcement discretion policies for certain compounded peptides

Recent announcements from the U.S. Department of Health and Human Services (HHS) and the Utah Division of Professional Licensing (DOPL) mark an important development in the evolving regulatory landscape surrounding peptide compounding.

On October 30, 2026, HHS published notice of a new interim enforcement discretion policy addressing certain peptide bulk drug substances used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. That same day, Utah DOPL announced that it would exercise similar limited enforcement discretion, consistent with the conditions established in the federal policy.

For Utah pharmacists and compounding pharmacies, these announcements provide a potential pathway for preparing certain peptide medications for individual patients, subject to strict regulatory requirements.

What Has Changed at the Federal Level?

The HHS policy establishes a limited enforcement discretion framework for six specific peptide bulk drug substances while the Food and Drug Administration (FDA) continues its evaluation of whether these substances should be included on the federal 503A bulk drug substances list.

The six peptides identified in the policy are:

• BPC-157

• Epitalon

• KPV

• MOTS-c

• Semax

• TB-500

Under the policy, HHS does not intend to take enforcement action against qualifying compounders solely for using these specified substances under the circumstances outlined in the guidance, provided all applicable conditions are satisfied.

The policy includes restrictions on the specific chemical forms and routes of administration permitted under the enforcement discretion framework.

Importantly, this announcement does not constitute FDA approval of these peptides, nor does it permanently add them to the list of bulk drug substances authorized for compounding under Section 503A.

The policy is interim in nature and may be revised as additional safety, quality, and regulatory information becomes available.

Read the official HHS policy:
HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances

Utah DOPL Announces Similar Enforcement Discretion

Following the federal announcement, Utah DOPL issued its own guidance confirming that it will exercise similar limited enforcement discretion within Utah.

DOPL emphasized that its approach will strictly follow the scope of the HHS interim policy and that every applicable condition must be satisfied.

For Utah pharmacies, DOPL specifically highlighted several important requirements:

• Licensed compounding pharmacies: Compounding and dispensing under Utah's policy are limited to state-licensed 503A compounding pharmacies.

• Patient-specific prescriptions: Each preparation must be compounded pursuant to a valid prescription for an individually identified patient.

• No office-use compounding: Compounding peptide preparations for clinic stock or general in-office use is prohibited under this policy.

• Adverse event reporting: Facilities must report adverse events to both the FDA and DOPL.

In addition to these state-specific reminders, pharmacies must comply with the remaining conditions established in the HHS policy, including requirements addressing ingredient sourcing, certificates of analysis, product labeling, reporting, and limitations on formulations.

Read the official Utah DOPL announcement:
Utah DOPL – Peptide Enforcement Discretion Policy, October 30, 2026

What This Means for Utah Pharmacists

The coordinated announcements are significant because they provide additional regulatory clarity for pharmacies evaluating whether to offer certain compounded peptide preparations.

However, the policies should not be interpreted as broad permission to compound or dispense any peptide product.

Pharmacies considering compounding under the interim policy should carefully review the complete HHS guidance, including its appendices, to verify that the specific peptide, chemical form, route of administration, ingredient source, and preparation meet the applicable conditions.

The federal policy also establishes requirements related to manufacturer registration, product testing and documentation, single-active-ingredient formulations, and adverse event and product quality reporting.

Patient safety remains an essential consideration. Compounded medications are not FDA-approved, and the FDA has not independently reviewed these preparations for safety, effectiveness, or quality before marketing.

Pharmacists should also evaluate the available clinical evidence, counsel patients appropriately, and maintain compliance with applicable federal and Utah pharmacy laws and standards.

UPhA Will Continue Monitoring Developments

The Utah Pharmacy Association recognizes the importance of providing pharmacists with timely information about changes affecting pharmacy practice, patient access, and regulatory compliance.

These recent announcements represent a meaningful development in peptide compounding policy, but additional federal rulemaking and regulatory guidance may follow.

UPhA will continue monitoring developments from HHS, the FDA, and Utah DOPL and sharing relevant updates with members as additional information becomes available.

Members involved in compounding or considering offering peptide preparations are encouraged to review both official policies in their entirety before making changes to their pharmacy operations.

Official Resources

U.S. Department of Health and Human Services
Full HHS Peptide Enforcement Discretion Policy and Appendices

Utah Division of Professional Licensing
Utah Peptide Enforcement Discretion Announcement

Federal Register
October 30, 2026 – Federal Notice of Availability